Onesource Specialty Pharma Reports Strong Q4 Recovery

Strong Q4 Performance Drives Recovery

Onesource Specialty Pharma Ltd. has reported a strong rebound in its fourth quarter for fiscal year 2026, with revenue surging 47% quarter-on-quarter to ₹428.20 crore. EBITDA also saw a significant jump, increasing over five-fold from the previous quarter to ₹91.90 crore. The company's adjusted profit after tax (PAT) also turned positive, reaching ₹390 million in Q4 FY26. This performance was primarily fueled by the successful launch of its semaglutide drug in India, along with positive contributions from new injectables and soft-gelatin product launches in the U.S. market.

Full-Year Results Show Contrast

This robust quarterly performance stands in contrast to the full fiscal year FY26 results. For the fiscal year, revenue dipped 2% year-over-year to ₹1,421.60 crore. EBITDA for FY26 decreased by 35% to ₹304.20 crore, and adjusted profit after tax (PAT) fell 68% to ₹739 million.

Significance of the Results

The strong Q4 results signal a potential turnaround after the challenges of FY26, bolstering investor confidence. Management has reaffirmed ambitious targets for fiscal year 2028, aiming for $400 million in organic revenue and an EBITDA margin of approximately 40%. This outlook provides investors with a clear vision for the company's sustained growth trajectory.

Company Background and Strategy

Onesource Specialty Pharma is an Indian pharmaceutical firm focused on manufacturing and marketing active pharmaceutical ingredients (APIs) and finished dosage forms, with a specialization in injectables and biologics. The company has been actively pursuing strategic growth, including the March 2024 launch of its diabetes drug, Semaglutide, in India. It has also secured agreements to expand its presence in the key U.S. injectables market.

Acquisition Strategy Update

The company had previously proposed acquiring specialty injectable assets from Steriscience. However, this acquisition has been paused, reportedly due to valuation concerns. Plans to revisit the deal are now targeted for post-FY28, indicating a temporary shift away from immediate inorganic expansion in that specific segment.

Investor Takeaways and Diversifying Drivers

For shareholders, the strong Q4 momentum suggests potential for improved near-term financial results. Growth drivers are diversifying, with increased focus on the U.S. injectables and soft-gelatin segments. The company's expanding biologics pipeline is also expected to support sustained growth into FY27.

Potential Risks

A key risk remains the paused Steriscience acquisition. The deferral of this deal, intended to enhance the company's injectables portfolio, carries the potential for future hurdles due to the underlying valuation concerns.

Peer Comparison

Laurus Labs, another player in APIs and FDFs with a biologics segment, serves as a peer. While Laurus Labs reported Q4 FY23 revenue of ₹1,330 crore and EBITDA of ₹301 crore, Onesource's recent Q4 FY26 performance highlights significant sequential growth potential within its specialized markets. Both companies experienced challenges reflected in their respective FY26 year-over-year figures.

Key Financial Metrics

Key full-year FY26 consolidated figures included revenue of ₹1,421.6 crore, EBITDA of ₹304.2 crore, and adjusted profit after tax of ₹739 million.

Looking Ahead

Investors will be monitoring the company's execution against its FY28 guidance of $400 million organic revenue and approximately 40% EBITDA margin. Key areas to track include progress in the U.S. injectables and soft-gelatin businesses, developments in the biologics pipeline, and any updates on the potential re-evaluation of the Steriscience acquisition or other inorganic growth opportunities. Assessing the sustainability of the strong Q4 performance trend will also be crucial.